What is the latest IPCALAB stock price?
The latest stored price for IPCALAB is Rs 1,911.20 as of 2026-08-21.
gimli
IPCALAB stock AI analysis
IPCALAB Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
IPCA LABORATORIES LTD is a mid-cap stock in Healthcare. This Gimli page shows the latest available IPCALAB price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,911.20
1W return
+10.21%
1M return
+6.24%
3M return
+16.75%
6M return
+31.83%
1Y return
+40.62%
Market cap
₹48,487.95 cr
PE
42.49
PB
5.09
ROE
+12.74%
ROCE
+16.42%
RSI
64.48
Turnover
₹37.09 cr
Why it can matter in screens
- Momentum: IPCALAB is above 50DMA, above 200DMA; RSI is 64.48.
- Returns: 1D +0.58%, 1W +10.21%, 1M +6.24%, 3M +16.75%, 1Y +40.62%.
- Trend levels: 52W high ₹1,945.10, 52W low ₹1,470.00, off high -1.74%.
- Liquidity: latest turnover is ₹37.09 cr; volume vs 20D is +0.29%.
- Valuation/profitability: PE 42.49, PB 5.09, ROE +12.74%, ROCE +16.42%.
- Growth: 3Y sales CAGR +15.83%, 3Y profit CAGR +34.27%.
Quick Answers
Is IPCALAB above its 50DMA and 200DMA?
IPCALAB is above 50DMA, above 200DMA. The latest 50DMA is 1,745.73 and the latest 200DMA is 1,549.84.
What are IPCALAB PE, ROE and ROCE?
IPCALAB has PE 42.49, ROE +12.74%, and ROCE +16.42% in Gimli's latest available snapshot.
How has IPCALAB performed recently?
IPCALAB has returned +6.24% over 1 month, +16.75% over 3 months, and +40.62% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,388.48 cr | 531.79 cr | 299.07 cr | 11.79 |
| 2025-12-31 | 2,392.50 cr | 571.19 cr | 326.27 cr | 12.86 |
| 2025-09-30 | 2,556.50 cr | 514.52 cr | 282.57 cr | 11.14 |
| 2025-06-30 | 2,308.85 cr | 449.08 cr | 233.21 cr | 9.19 |
| 2025-03-31 | 2,246.69 cr | 249.63 cr | 67.82 cr | 2.67 |
| 2024-12-31 | 2,245.37 cr | 483.19 cr | n/a | nan |
| 2024-09-30 | 2,354.90 cr | 467.74 cr | n/a | 9.05 |
| 2024-06-30 | 2,092.63 cr | 413.33 cr | 192.24 cr | 7.58 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 9,646.33 cr | 2,066.58 cr | 1,141.12 cr | 44.64 |
| 2025-03-31 | 8,939.59 cr | 1,613.89 cr | 737.68 cr | 29.08 |
| 2024-03-31 | 7,622.41 cr | 1,337.20 cr | 547.35 cr | 21.57 |
| 2023-03-31 | 6,206.85 cr | 1,051.94 cr | 471.32 cr | 18.58 |
| 2022-03-31 | 5,491.22 cr | 1,375.38 cr | 860.37 cr | 34.85 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 12,370.19 cr | 437.12 cr | 808.76 cr | 9,524.06 cr |
| 2025-03-31 | 11,760.55 cr | 167.17 cr | 1,362.74 cr | 8,388.27 cr |
| 2024-03-31 | 11,101.28 cr | 208.91 cr | 1,438.36 cr | 7,727.00 cr |
| 2023-03-31 | 8,626.43 cr | 1,257.85 cr | 1,481.27 cr | 5,915.32 cr |
| 2022-03-31 | 7,623.53 cr | 275.19 cr | 807.22 cr | 5,540.73 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,141.97 cr | 486.02 cr | n/a |
| 2025-03-31 | 1,321.32 cr | 545.75 cr | n/a |
| 2024-03-31 | 944.65 cr | 533.36 cr | n/a |
| 2023-03-31 | 805.81 cr | 311.34 cr | n/a |
| 2022-03-31 | 856.07 cr | 377.12 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +44.72% | +10.73% | +37.37% | +31.15% | +7.18% | +0.00% |
| 2026-03-31 | +44.72% | +10.63% | +37.45% | +31.24% | +7.20% | +0.00% |
| 2025-12-31 | +44.72% | +10.63% | +37.32% | +30.52% | +7.33% | +0.00% |
| 2025-09-30 | +44.72% | +10.43% | +36.77% | +30.04% | +8.07% | +0.00% |
| 2025-06-30 | +44.72% | +10.67% | +36.20% | +29.61% | +8.41% | +0.00% |
| 2025-03-31 | +44.72% | +10.76% | +36.06% | +29.63% | +8.46% | +0.00% |
| 2024-12-31 | +44.72% | +11.07% | +35.68% | +29.63% | +8.53% | +0.00% |
| 2024-09-30 | +46.30% | +10.83% | +34.23% | +28.55% | +8.64% | +0.00% |
| 2024-06-30 | +46.30% | +10.85% | +33.78% | +28.52% | +9.06% | +0.00% |
| 2024-03-31 | +46.30% | +10.51% | +34.37% | +28.83% | +8.82% | +0.00% |
| 2023-12-31 | +46.29% | +10.27% | +34.52% | +29.25% | +8.93% | n/a |
| 2023-09-30 | +46.29% | +9.86% | +35.05% | +30.23% | +8.81% | +0.00% |
| 2023-06-30 | +46.29% | +10.05% | +35.19% | +30.27% | +8.48% | +0.00% |
| 2023-03-31 | +46.29% | +10.58% | +34.06% | +29.94% | +9.07% | +0.00% |
| 2022-12-31 | +46.29% | +10.46% | +34.03% | +29.79% | +9.22% | +0.00% |
| 2022-09-30 | +46.29% | +10.57% | +33.79% | +29.71% | +9.35% | +0.00% |
| 2022-06-30 | +46.29% | +0.24% | +44.10% | n/a | n/a | +0.00% |
| 2022-03-31 | +46.29% | +0.24% | +43.72% | n/a | n/a | +0.00% |
| 2021-12-31 | +46.29% | +0.24% | +42.36% | n/a | n/a | +0.00% |
| 2021-09-30 | +46.29% | +0.22% | +43.70% | n/a | n/a | n/a |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze IPCA LABORATORIES with valuation, momentum and industry peers
- Compare IPCALAB with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare IPCALAB with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.